Food and Drug Administration: FDA Approves New Medication for Chronic Weight Management American Diabetes Association: Tirzepatide Returns to the Spotlight on the Final Day of the Scientific Sessions Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine : Sheryl Huggins Salomon Author Sheryl Huggins Salomon has spent her career equipping people with information to help improve their well-being and prospects in life

MOUNJARO The most common side effects of Mounjaro (tirzepatide) include: Nausea Diarrhea Vomiting Constipation Decreased appetite Stomach pain or upset stomach Indigestion or heartburn Burping and excess gas Injection site reactions such as redness or itching Dizziness Rash or itching Hair loss Low blood pressure Tiredness OZEMPIC SIDE EFFECTS The most common side effects of the Ozempic weight loss injection are: Nausea Diarrhea Stomach (abdominal) pain Vomiting Constipation SAXENDA SIDE EFFECTS Common side effects of the Saxenda weight loss injection include: Heartburn Nausea or vomiting Diarrhoea Constipation Increased heart rate Increased risk of gallstones Hypoglycaemia (low blood sugar) Lightheadedness Feeling of intense hunger Feeling sick and shaky WEGOVY SIDE EFFECTS The most common side effects of the Wegovy weight loss injection are: Nausea Vomiting Diarrhoea Constipation Fatigue Headaches Feeling lightheaded Excess wind (flatulence) Development of gallstones Gastroesophageal reflux Injection site reactions Hair loss and hypoglycemia in patients with type 2 diabetes While these side effects are undoubtedly unpleasant, most of them are likely to resolve themselves in a few days after an individual stops taking their medication

Power Meal Slim GLP-1 (chocolate, vanilla, or strawberry): A lower-calorie, meal-replacement-style smoothie made with protein powder, fruit, and almond milk, with a smoother texture that may be easier to tolerate
Pharmacists ensure the medicine is appropriate, offer advice, and check if the person needs to see a doctor
In human cosmetic split-face studies (n values typically 20 to 93 participants), measurable skin density and fine-line improvements appear from week 4, with most outcomes reported at 8 to 12 weeks of daily topical use